The major factors for the growth of the hematology analyzers market include the rising burden of blood disorders, increasing technological advancements, and rising adoption rates of automated hematology instruments.
Blood disorders have become a global health issue with different causes, and are associated with high mortality. Blood disorders, such as anemia, blood cancers, hemorrhagic conditions, and infections in the blood, affect millions of people each year across all age groups. According to Commonwealth of Australia, more than 330,000 affected infants are born each year (83% sickle cell disorders and 17% thalassaemias), around 7% of pregnant women are carriers of hemoglobin disorders and over 1% of couples are at risk at a global level. As per the World Federation of Hemophilia, in 2019, the prevalence of hemophilia among men was found to be around 17 per 100,000 male, globally. Early diagnosis and treatment are the best ways to protect the quality of life for a patient with a blood cell disorder. Hence, increasing burden of blood disorders are likely to drive the market in the future.
Key Market Trends
Clinical Testing Laboratories is the Segment by End-User expected to Hold Largest Market Share
The clinical laboratories as end users are the centers where hematology tests are performed. Usually, they have high-quality equipment and the results obtained from them are accurate. The automation of laboratories have increased the equipment costs in this segment, however, the analyzers are not frequently replaced in these laboratories. The clinical testing laboratories perform various tests on whole blood, serum, urine, cerebrospinal fluids, and other body fluids. Furthermore, convenience and accurate results are the two major reasons driving the growth of the segment over the forecast period.
North America is Expected to Dominate the Studied Market
The market for hematology analyzers in the North America region is growing at a steady pace. This can be attributed to the increasing burden of blood disorders and the growth in adoption of hematology analyzers by the diagnostic industry. For instance, anemia, which is a common disorder, affects more than three million Americans, particularly women of ‘childbearing-age’. In the United States, there are a number of associations helping, both, clinicians and scientists across the world, who are working to conquer such blood diseases. In addition, many centers in the state are international leaders in the diagnosis and treatment of blood diseases and collaborate in many research projects to improve diagnosis and treatment options for blood diseases. These factors drives the demand and importance of allergy immuntherapy medication in the North American region.
The market studied is a fragmented market owing to the presence of various market players. Some of the market players are Abbott Laboratories, Danaher Corporation, Bio-Rad Laboratories, Boule Diagnostics AB, F. Hoffmann-La Roche Ltd, Hobira Ltd, Nihon Kohden Corporation, Shenzhen Mindray Bio-Medical Electronics Co., Ltd., Siemens Healthineers, and Sysmex Corporation
Reasons to Purchase this report:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support